Search

everythinglearnresearchcommunity

for

Search:↓

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Pexidartinib often causes liver issues and fatigue, especially in women.

Tofacitinib may help regrow hair in alopecia areata patients.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Abrocitinib may effectively treat stubborn alopecia universalis.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.

Upadacitinib may effectively treat resistant lichen planopilaris.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Bempikibart may help regrow hair in people with alopecia areata.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Tofacitinib taken by mouth helps treat hair loss in children.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.